Humana (NYSE:HUM) Stock Price Expected to Rise, Barclays Analyst Says

Humana (NYSE:HUM) had its target price boosted by Barclays from $253.00 to $255.00 in a research note published on Wednesday morning,Benzinga reports. They currently have an equal weight rating on the insurance provider’s stock.

Several other research firms have also recently commented on HUM. Morgan Stanley raised their target price on shares of Humana from $288.00 to $301.00 and gave the stock an “equal weight” rating in a research report on Tuesday, December 17th. TD Cowen upped their target price on Humana from $261.00 to $268.00 and gave the stock a “hold” rating in a report on Monday, November 4th. Royal Bank of Canada lowered their target price on Humana from $400.00 to $265.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th. Oppenheimer reduced their price target on Humana from $400.00 to $280.00 and set an “outperform” rating on the stock in a research note on Thursday, October 3rd. Finally, Deutsche Bank Aktiengesellschaft lowered their price objective on Humana from $349.00 to $250.00 and set a “hold” rating for the company in a research report on Thursday, October 3rd. Twenty investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $302.80.

Humana Stock Up 0.2 %

NYSE HUM opened at $294.47 on Wednesday. Humana has a 1 year low of $213.31 and a 1 year high of $406.46. The stock has a market capitalization of $35.46 billion, a PE ratio of 26.08, a PEG ratio of 2.15 and a beta of 0.55. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.76 and a quick ratio of 1.76. The business’s 50-day moving average is $274.02 and its 200 day moving average is $305.79.

Humana (NYSE:HUM) last posted its earnings results on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.48 by $0.68. Humana had a return on equity of 13.20% and a net margin of 1.18%. The firm had revenue of $29.30 billion for the quarter, compared to analysts’ expectations of $28.66 billion. Sell-side analysts forecast that Humana will post 16.11 earnings per share for the current year.

Insider Activity

In related news, insider Timothy S. Huval sold 3,703 shares of the stock in a transaction that occurred on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total transaction of $948,930.78. Following the transaction, the insider now owns 8,181 shares in the company, valued at $2,096,463.06. This represents a 31.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.32% of the company’s stock.

Institutional Investors Weigh In On Humana

A number of large investors have recently added to or reduced their stakes in HUM. Creative Financial Designs Inc. ADV grew its holdings in shares of Humana by 244.0% in the third quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider’s stock worth $27,000 after acquiring an additional 61 shares during the period. Atwood & Palmer Inc. bought a new stake in shares of Humana during the 3rd quarter valued at about $29,000. Ashton Thomas Securities LLC purchased a new stake in shares of Humana during the 3rd quarter valued at about $31,000. Your Advocates Ltd. LLP lifted its stake in shares of Humana by 81.8% in the 3rd quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider’s stock worth $32,000 after purchasing an additional 45 shares during the period. Finally, LRI Investments LLC boosted its holdings in shares of Humana by 1,021.4% in the third quarter. LRI Investments LLC now owns 157 shares of the insurance provider’s stock worth $50,000 after buying an additional 143 shares during the last quarter. Institutional investors own 92.38% of the company’s stock.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.